Amgen Inc. Total Long-Term Debt
Amgen Inc. (AMGN) had Total Long-Term Debt of $57.30 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LongTermDebt · last filed 2026-08-05
- 2026-06-30: Long-term Debt $57.30B.
- 2026-03-31: Long-term Debt $57.32B.
- 2025-12-31: Long-term Debt $54.60B.
- 2025-09-30: Long-term Debt $54.59B.
| Period end | Long-term Debt | Long-term Debt as first filed |
|---|---|---|
| 2026-06-30 | $57.30B 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $57.32B 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $54.60B 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $54.59B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $56.20B 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $57.38B 10-Q · filed 2025-05-02 | |
| 2024-12-31 | $60.10B 10-K · filed 2026-02-13 | |
| 2024-09-30 | $60.40B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $62.65B 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $64.02B 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $64.61B 10-K · filed 2025-02-14 | |
| 2023-09-30 | $60.47B 10-Q · filed 2023-10-31 | |
| 2023-06-30 | $61.54B 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $61.59B 10-Q · filed 2023-04-28 | |
| 2022-12-31 | $38.95B 10-K · filed 2024-02-14 | |
| 2022-09-30 | $38.70B 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $36.52B 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $36.85B 10-Q · filed 2022-04-28 | |
| 2021-12-31 | $33.31B 10-K · filed 2023-02-09 | |
| 2021-09-30 | $37.58B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $32.78B 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $32.69B 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $32.99B 10-K · filed 2022-02-16 | |
| 2020-09-30 | $34.29B 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $34.22B 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $31.85B 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $29.90B 10-K · filed 2021-02-09 | |
| 2019-09-30 | $29.79B 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $30.61B 10-Q · filed 2019-07-31 | |
| 2019-03-31 | $33.02B 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $33.93B 10-K · filed 2020-02-12 | |
| 2018-09-30 | $34.43B 10-Q · filed 2018-10-31 | |
| 2018-06-30 | $34.50B 10-Q · filed 2018-07-27 | |
| 2018-03-31 | $35.54B 10-Q · filed 2018-04-25 | |
| 2017-12-31 | $35.34B 10-K · filed 2019-02-13 | |
| 2017-09-30 | $35.78B 10-Q · filed 2017-10-26 | |
| 2017-06-30 | $35.06B 10-Q · filed 2017-07-26 | |
| 2017-03-31 | $34.09B 10-Q · filed 2017-04-27 | |
| 2016-12-31 | $34.60B 10-K · filed 2018-02-13 | |
| 2016-09-30 | $35.32B 10-Q · filed 2016-10-28 | |
| 2016-06-30 | $33.22B 10-Q · filed 2016-07-29 | |
| 2016-03-31 | $34.31B 10-Q · filed 2016-05-02 | |
| 2015-12-31 | $31.43B 10-K · filed 2017-02-14 | $31.56B 10-K · filed 2016-02-16 |
| 2015-09-30 | $31.76B 10-Q · filed 2015-11-02 | |
| 2015-06-30 | $31.95B 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $30.34B 10-Q · filed 2015-04-27 | |
| 2014-12-31 | $30.59B 8-K · filed 2016-10-31 | $30.71B 10-K · filed 2015-02-19 |
| 2014-09-30 | $32.98B 10-Q · filed 2014-10-29 | |
| 2014-06-30 | $33.33B 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $32.02B 10-Q · filed 2014-04-30 | |
| 2013-12-31 | $32.13B 10-K · filed 2015-02-19 | |
| 2013-09-30 | $27.19B 10-Q · filed 2013-10-29 | |
| 2013-06-30 | $23.91B 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $23.89B 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $26.53B 10-K · filed 2014-02-24 | |
| 2012-09-30 | $26.48B 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $24.38B 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $21.41B 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $21.43B 10-K · filed 2013-02-27 | |
| 2011-09-30 | $13.96B 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $13.93B 10-Q · filed 2011-08-08 | |
| 2011-03-31 | $10.91B 10-Q · filed 2011-05-10 | |
| 2010-12-31 | $13.36B 10-K · filed 2012-02-29 | |
| 2010-09-30 | $13.29B 10-Q · filed 2010-11-08 | |
| 2010-06-30 | $11.73B 10-Q · filed 2010-08-09 | |
| 2009-12-31 | $10.60B 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |